Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ABBV-400 versus Lonsurf + bevacizumab in c-Met overexpressing metastatic refractory colorectal cancer
MOH_2024-09-29_013669Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telisotuzumab adizutecan in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Not reported. Started Sep 2024; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on MOH_2024-09-29_013669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-29_013669.